Why does bad data still reach your AI systems?
Your dashboards score data quality, but the score arrives after the damage. A data contract moves the fix upstream, before anyone consumes the data.
Why does your best AI credit model still fail the regulator?
The AI that scores credit best is often the AI you cannot defend. Regulators and customers now punish any model that cannot show its work.
How do small fintechs afford AI compliance without a bank's budget?
European rules are multiplying while funding gets selective. Small fintechs face a squeeze: buy compliance tools, build them, or partner with the startups now pitching regulators directly.
Why does FDA approval still leave medical AI unsafe?
Regulators clear AI devices fast, then lose sight of them. Approval was the easy part; the hard part starts the day the device meets real patients.
What breaks when you let an AI bot trade your money?
Institutions quietly use AI in trading, yet the bots sold to retail investors mostly promise what fraudsters promise. Here is how to tell the two apart.
Why do big banks keep blocking your AI agent from your money?
Banks are opening read access to AI agents but the biggest US names refuse to let them move money. The blocker is liability, not technology.
Why is fraud detection AI's first easy win in finance?
Fraud detection lets AI be wrong cheaply, so it ships first. Agentic AI that moves money fails the trust test regulators demand.
Can AI underwriting be fair without slowing it down?
AI underwriting now cuts mortgage reviews from 15 hours to minutes, but unsecured bad loans show what unchecked credit algorithms cost lenders and borrowers.
What do mental health chatbots actually solve?
Millions now talk to chatbots before therapists. The evidence says they help with access and first-step support, but fail exactly where care gets hard.
Should patients see what the AI heard in their visit?
A court says ambient AI recordings are not medical records, even as vendors push AI deeper into clinical decisions.
How do you kill a failing drug before it costs billions?
Novartis lost $30 billion in market value when a late-stage trial missed. An AI start-up had predicted the failure months earlier using virtual patients.